Understanding a Cell's 'Doorbell': Drug Design Advances are the Research Goal
News Apr 13, 2018 | Original story from DOE/LOS Alamos National Laboratory
A multi-institutional project to understand one of the major targets of human drug design has produced new insights into how structural communication works in a cell component called a G protein-coupled receptor (GPCRs), basically a "doorbell" structure that alerts the cell of important molecules nearby. Understanding the structure and function of the receptor more deeply will enable better drug development.
"It's a huge field of active research in academia and industry because if we can figure out precisely how GPCRs work, then we can more easily design drugs to change their behavior and thereby control pain, hunger, and more," said coauthor Christopher Neale, a researcher with the Center for Nonlinear Studies at Los Alamos National Laboratory. "This work helps us in understanding the receptors' function as a means to enable future drug discovery. For instance, if calcium binding can turn off a GPCR, then one may use that knowledge in a guided search for drugs that either promote or inhibit calcium binding depending on the desired health outcome."
GPCRs are a family of membrane proteins that transmit information into our cells. They respond to things like adrenaline and opioid drugs, and they are the largest class of human drug targets. The research reported this week in Nature Communications describes the regulation of GPCRs by physiological ions such as sodium, calcium and magnesium.
This article has been republished from materials provided by DOE/LOS Alamos National Laboratory. Note: material may have been edited for length and content. For further information, please contact the cited source.
Autoscribe Informatics, a specialist provider of Laboratory Information Management Systems (LIMS), has expanded its worldwide distribution network. Corporación Científica Venezolana, CA has been appointed to cover South America, while V*I*Production sp z.o.o. will represent Autoscribe in Germany and Poland.
Researchers have figured out precisely why one drug binds to the serotonin receptor 5-HT2BR and activates it to cause heart problems while very similar drugs do not. They've also discovered why a third drug acts like a 5-HT2BR antagonist - it blocks the receptor's activity - while the very well-known similar hallucinogenic drug LSD does not.READ MORE